Por favor, use este identificador para citar o enlazar este ítem:
https://www.arca.fiocruz.br/handle/icict/6896
Tipo
ArtículoDerechos de autor
Acceso restringido
Objetivos de Desarrollo Sostenible
03 Saúde e Bem-EstarColecciones
Metadatos
Mostrar el registro completo del ítem
DEVELOPING VACCINES TO COMBAT HOOKWORM INFECTION AND INTESTINAL SCHISTOSOMIASIS
Afiliación
George Washington University. Department of Microbiology, Immunology, and Tropical Medicine. Washington, USA / Sabin Vaccine Institute. Washington, USA.
George Washington University. Department of Microbiology, Immunology, and Tropical Medicine. Washington, USA / Oswaldo Cruz Foundation. Centro de Pesquisas René Rachou. Belo Horizonte, MG, Brazil.
George Washington University. Department of Microbiology, Immunology, and Tropical Medicine. Washington, USA / Oswaldo Cruz Foundation. Centro de Pesquisas René Rachou. Belo Horizonte, MG, Brazil.
James Cook University. Queensland Tropical Health Alliance. Cairns, Australia.
James Cook University. Queensland Tropical Health Alliance. Cairns, Australia.
George Washington University. Department of Microbiology, Immunology, and Tropical Medicine. Washington, USA / Oswaldo Cruz Foundation. Centro de Pesquisas René Rachou. Belo Horizonte, MG, Brazil.
George Washington University. Department of Microbiology, Immunology, and Tropical Medicine. Washington, USA / Oswaldo Cruz Foundation. Centro de Pesquisas René Rachou. Belo Horizonte, MG, Brazil.
James Cook University. Queensland Tropical Health Alliance. Cairns, Australia.
James Cook University. Queensland Tropical Health Alliance. Cairns, Australia.
Resumen en ingles
Hookworm infection and schistosomiasis rank among the most important health problems in developing countries. Both cause anaemia and malnutrition, and schistosomiasis also results in substantial intestinal, liver and genitourinary pathology. In sub-Saharan Africa and Brazil, co-infections with the hookworm, Necator americanus, and the intestinal schistosome, Schistosoma mansoni, are common. The development of vaccines for these infections could substantially reduce the global disability associated with these helminthiases. New genomic, proteomic, immunological and X-ray crystallographic data have led to the discovery of several promising candidate vaccine antigens. Here, we describe recent progress in this field and the rationale for vaccine development.
Compartir